

REFERENCES

- **Abdel-Wahed MA, Awad HA, El-Barbary MN, Abbaas W (2001):** Focal infections in neonates recovering from generalized sepsis: The value of serial CRP measurement. *The Egyptian Journal of Neonatology*; (2): 2.
- **Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S (2002):** The epidemiology of hematogenous candidiasis caused by different *Candida* species. *Clin Infect Dis*; 24:1122-1128.
- **Abelson JA, Moore T, Bruckner D, Deville J, Nielsen K (2005):** Frequency of fungemia in hospitalized pediatric patients over 11 years at a tertiary care institution. *Pediatrics* 116:61–67
- **Ables AZBN, Valainis GT, et al. (2000):** Fluconazole prophylaxis of severe *Candida* infection in trauma and postsurgical patients: a prospective, double blind, randomized, placebo-controlled trial. *Infect Dis Clin Pract*; 9:1066.
- **Adler A, Yaniv I, Solter E, Freud E, Samra Z, Stein J, et al. (2006):** Catheter associated bloodstream infections in pediatric hematology-oncology patients: factors associated with catheter removal and recurrence. *J Pediatr Hematol Oncol*; 28:23-8.
- **Ahmad E, Said A, Neveen A, Nasser K (2009):** Early diagnosis of fungal infection in neonates. pp 85-94

- **Ahmad S, Khan Z, Mustafa SA and Khan ZU (2003):** Epidemiology of *Candida* colonization in an intensive care unit of a teaching hospital in Kuwait. *Med Mycol*; 41:487-493.
- **Al-Assiri A, Al-Jastaneiah S, Al-Khalaf A, Al-Fraikh H, Wagoner MD (2006):** Late-onset donor-to-host transmission of *Candida glabrata* following corneal transplantation. *Cornea*; 25:123-125.
- **Alberth M, Majoros L, Kovalecz G, Borbás E, Szegedi I, Márton IJ, et al. (2006):** Significance of oral candida infections in children with cancer. *Pathol Oncol Res*; 12(4):237-41.
- **Aliff TB; Maslak PG; Jurcic JG (2003):** Refractory *Aspergillus* pneumonia in patients with acute leukaemia: successful therapy with combination caspofungin and liposomal amphotericin B. *Cancer*; 97: 1025-1032.
- **Aliyu SH, Enoch DA, Abubakar II, Carmichael RAJ, Farrington M and Lever AML (2006):** Candidaemia in a large teaching hospital. *Eur J clin Microbiol Infect Dis*; 23:745-50.
- **Aly R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, et al. (2001):** A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. *Clin Infect Dis*; 33:1447–54.
- **Almirante B, Rodriguez D, Park BJ. Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Saballs P,**

- Fridkin SK, Morgan J, Rodriguez-Tudela JL, Warnock DW, Pahssia A (2005).** Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. *J Clin Microbiol* 43:1829-1835.
- **Anthony P, Borzotta MD, Kathleen Beardsley RN and MS (1999):** Candida Infections in Critically Ill Trauma Patients. *Arch Surg*; 134:657-665.
 - **Ashley ESD, Lewis R, Lewis JS, Martin C, Andes D (2006):** Pharmacology of systemic antifungal agents. *CID*; 43(1): S28-S39.
 - **Baily GG, Moore CB, Essayag SM, de Wit S, Burnie JP, Denning DW (2001):** Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus. *Clin Infect Dis*; 25:161-3.
 - **Bar W and Hecker H (2002):** Diagnosis of systemic Candida infections in patients of intensive care unit. Significance of serum antigens and antibodies. *Mycosis*; 45 (1-2): 22-28.
 - **Barchiesi F, Morbiducci V, Ancarani F, Scalise G (2002):** Emergence of oropharyngeal candidiasis caused by non-albicans species of candida in HIV-infected patients. *Eur J Epidemiol*; 9:455-456.
 - **Barnes RA (2008):** Early diagnosis of fungal infection in immunocompromised patients. *J Antimicrob Chemo*; 61(1): i3–i6.

- **Beak SH; Chae D; Hough D; Byum B; Cho (1998):** Detection and differentiation of causative fungi of onychomycosis using PCR amplification and restriction enzyme analysis. *Int. J. Dermatol*; 37: 682-686.
- **Benjamin DK Jr; Ross K; McKinney RE Jr; Auten R; Fisher RG (2000):** When to suspect fungal infection in neonates: a clinical comparison of *C. albicans* and *C. parapsilosis* fungemia with coagulase-negative staphylococcal bacteremia. *Pediatrics*; 106: 712-718.
- **Blumberg HM, Jarvis WR and Soucie JM (2001):** Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. *Clin Infect Dis*; 33:177-186.
- **Blyth CC, Palasanthiran P, O'Brien TA (2007):** Antifungal therapy in children with invasive fungal infections: A Systematic review. *Pediatrics*; 119(4): 772-784.
- **Botas CM; Kurlat I; Younf SM; Sola A (1995):** Disseminated candidal infections and intravenous hydrocortisone in preterm infants. *Pediatr*; 95: 883-7.
- **Boucher HW, Groll AH, Chiou CC, Walsh TJ (2004):** Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. *Drugs*; 64:1997-2020.

- **Bow YF; Herwaldt LA; Pfaller MA (2002):** Trends in antifungal use and epidemiology of nosocomial yeast infections in a university Hospital. J Clin Microbiol; 37: 531-537.
- **Brasch J (2004):** standard and recently developed methods for the differentiation of derma-rophytes.Hautarzt.Feb.; 55(2):136-142.
- **Brenner GM (2000):** Antifungal drugs. In: Pharmacology, 1st edn. Ch. 42, P; 441-447. W.B. Saunders Company, Philadelphia.
- **Busca A, Locatelli F, Barbui A, et al. (2006):** Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. Transplant Proc; 38:1610.
- **Cahan H and Deville JG. (2003):** Invasive fungal infections in a neonatal intensive care unit: a five year retrospective review. Presented at the 41st Annual Meeting of the Infectious Diseases Society of America; San Diego, CA
- **Caillot D, Couaillier JF, Bernard A, et al. (2001):** Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol; 19:253.
- **Candoni A, Mestroni R, Damiani D, Tiribelli M, Michelutti A, Silvestri F, Castelli M, Viale P, Fanin R (2005):** Caspofungin as first line therapy of pulmonary invasive fungal infections in 32

- immunocompromised patients with hematologic malignancies Eur J Haematol. 75 (3)-227-233.
- **Carter GR, Wise DJ (2004):** Essentials of veterinary bacteriology and mycology. 6th ed. Wiley-Blackwell, pp 245-246.
 - **Cazgreen S (2008):** Ringworm (onychomycosis) on Flickr.www.yahoo.com
 - **Charles PE, Dalle F, Aube H, et al. (2005):** candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med; 31:393.
 - **Chayakulkeeree M, Ghannoum MA and Perfect JR (2006):** Zygomycosis: the reemerging fungal infection. Eur J Clin Microbiol Infect Dis; 25:215.
 - **Chen F, Buchheidt D, Skladny H, Baust C, Hehlmann R (2004):** Systemic infections with Candida spp. and aspergillus spp. in immunocompromised patients with hematological malignancies; 46 (3): 219-228.
 - **Cheng MF, Yang YL, Yao TJ, Lin CY, Liu JS, Tang RB, et al. (2005):** Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species. BMC Infect Dis; 5:22.
 - **Chen SCA, Sorrell TC (2007):** New drugs, old drugs; Antifungal agents. MJA; 187:404–409.

- **Collier L, Balows A, Sussman M (2002):** Topley & Wilson's Microbiology and Microbial Infections. 9th ed. vol. 4. Arnold, London, Sydney, Auckland, New York
- **Corpus K, Hegeman-Dingle R, Bajjoka I (2004):** Candida kefyr, an uncommon but emerging fungal pathogen: Report of two cases. Pharmacotherapy; 24:1084-1088.
- **Da Silva CL, Dos Santos RM and Colombo AL (2001):** Cluster of Candida parapsilosis primary bloodstream infection in a neonatal intensive care unit. Braz. J. Infect. Dis; 5:32-36.
- **Das S, Shivaprakash MR, Chakrabarti A (2009):** New antifungal agents in pediatric practice. Indian Pediatrics; 46:225-231.
- **Deborah LR, Yamamura MD, Coleman Rotstein MD, Lindsay E, Nicolle MD, Stratis Ioannou MSc and the Fungal Disease Registry of the Canadian Infectious Disease Society (1999):** Candidemia at selected Canadian sites. CMAJ; 160:493-9.
- **De Backer M, De Vroey C, Lesaffre E, Scheys I, De Keyser P (1998):** Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol; 38:S57–S63.
- **De Vos MM, Cuenca-Estrella M, Boekhout T, Theelen B, Matthijs N, Bauters T, et al (2005):** Vulvovaginal candidiasis in a Flemish patient population. Clin Microbiol Infect, 11:1005-11.

- **De Vroey C, Desmet P, LI ZQ, Mukamurangwa P, Raes-Wuytack C (2000):** Farther studies on the in vitro antifungal activity of amorolfine. *Mycosis*. 39: 41-44.
- **Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht D, Theiel E, Hass A, Ruhnke M, Lode H (2003):** Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. *Clin Infect Dis*; 34: 564-56-71.
- **Dimopoulos G, Velegraki A, Pefanis A, et al. (2007):** Candiduria in critically ill patients: an early candidemia marker when coupled with multiple blood specimens PCR assays. *Hepatogastroenterology*; 54:354.
- **Doble M, Kumar KA (2006):** Experimental and modelling studies on antifungal compounds. *CEJC*; 4(3) 428–439.
- **Ellis D, Hermanis R (2002):** Courtesy of Geraldine Kaminski medical mycology library.
- **Ellis ME, Clink H, Ernst P, Halim MA, Padmos A, Spence D, et al. (2004):** Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. *Eur J Clin Microbiol Infect Dis*; 13(1):3-11.
- **Emmanuel Roilides, Evangelia Farmaki, Joanna Evdoridou, Andrea Francesconi, Miki Kasai, Joanna Filioti, Maria Tsivitanidou, Danai Sofianou, George Kremenopoulos and Thomas Walsh J (2003):** *Candida tropicalis* in a Neonatal Intensive Care Unit:

- Epidemiologic and Molecular Analysis of an Outbreak of Infection with an Uncommon Neonatal Pathogen. *J Clin Microbiol*; 41(2):735–741.
- **EORTC International Antimicrobial Therapy Cooperative Project Group (1989):** Empiric antifungal therapy in febrile granulocytopenic patients. *AM J Med*; 86:668–72.
 - **Erdem H, Cetin M, Timuroglu T, Cetin A, Yanar O, Pahsa A (2003):** Identification of yeasts in public hospital primary care patients with or without clinical vaginitis. *Aust NZJ Obstet Gynaecol*; 43:312-6.
 - **Faggi E, Pini G, Campisi E, Martinelli C, Difonzo E (2005):** Detection of *Candida dubliniensis* in oropharyngeal samples from human immunodeficiency virus infected and non-infected patients and in a yeast culture collection. *Mycoses*; 48:211-215.
 - **Favre B and Ryder NS (2000):** Characterization of squalene epoxidase activity from the dermatophyte *Trichophyton rubrum* and its inhibition by Terbinafine and other antimycotic agents. *Antimicrob. Ag. Chemother.* 40: 443-447.
 - **Fidel PL (2002):** Immunity to candida. *Oral Dis*; 8:69-75.
 - **Flahaut MD, Sanglard M, Monod S, Bille M, Rossier (2002):** Rapid detection of *C. albicans* in clinical samples by DNA amplification of common regions from *C. albicans* secreted aspartic proteinase genes. *J Clin Microbiol*; 36 (2): 395-401.

- **Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, et al. (2001):** Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. *Leuk Lymphoma*; 40:511–20.
- **Forbes BA, Sahm DF, Weissfeld AS (2002):** Mycology p. 711-798. In. *Bailey & Scott's Diagnostic Microbiology*, 11th edition. Mosby, Inc. St. Louis, Missouri.
- **Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T (2006):** Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. *Pediatrics*; 117:1680-1687.
- **Friedman EP, Miller RF, Severn A, Williams IG and Shaw PJ (2000):** Cryptococcal pneumonia in patients with the acquired immunodeficiency syndrome. *Clin Radiol*; 50: 756-60.
- **Garcia-Rwz JC; Arilla MC; Regulez P; Quindos G; Alvarez A; Ponton J (1997):** detection of antibodies to *Candida albicans* germ tubes for the diagnosis and therapeutic monitoring of invasive candidiasis in patients with haematological malignancies. *J Clin Microbiol*; 35: 3284-3287.
- **Gillespie MB, O'Malley BW (2000):** An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. *Otolaryngol Clin N Amer*; 33:323-334,IX
- **Glasmacher A, PrenticeA, Gorschluter M (2003):** Itraconazole prevents invasive fungal infections in neutropenic patients treated for

- haematological malignancies: evidence from a meta-analysis of 3,597 patients. *J Clin Oncol*; 21: 4615-4626.
- **Golan Y, Wolf MP, Pauker SG, et al. (2005):** Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. *Ann Intern Med*; 143:857.
 - **Gorschluter M, Marklein G, Hofling K, Clarenbach R, Baumgrtner S, Hahn C, et al (2002):** Abdominal infections in patients with acute leukaemia: a prospective study applying ultrasonography and microbiology. *Br J Haematol*;117:351-358. .
 - **Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. (2007):** Imaging findings in acute invasive pulmonary aspergillosis: Clinical significance of the halo sign. *Clin Infect Dis*; 44:373–379.
 - **Griffin DH (2004):** *Fungal Physiology* (2nd ed.). Wiley-Liss. New York.
 - **Grimaudo NJ, Nesbitt WE, Clark WB (2004):** Coaggregation of *Candida albicans* with *Actinomyces* species. *Oral Microbiol Immunol*; 11: 59–61.
 - **Groll AH, Kolve H (2004):** Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. *Eur J Clin Microbiol Infect Dis*; 23:256–270.

- **Groll AH and Walsh TJ (2001):** Capsofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. *Expert Opin Investig Drugs*; 10: 1545-1558.
- **Gumbo T, Taeye AJ, Mawhorter S, McHenry MC, Lytle BH, Cosgrove DM, et al. (2000):** Aspergillus valve endocarditis in patients without prior cardiac surgery. *Medicine*; 79:261-268.
- **Gupta N, Haque A, Lattif AA, Narayan RP, Mukhopadhyay G, Prasad R (2004):** Epidemiology and molecular typing of Candida isolates from burn patients. *Mycopathologia*; 158:397-405.
- **Hay RD (2006):** Fungal infections. *Clinics in Dermatology*; 24(3):201-12.
- **Hay RL (2000):** Yeast infection. *Cutaneous Mycology. Dermatologic Clinics.*; 14: 113-124.
- **Hazen KG and Howell SA (2003):** Candida, Cryptococcus, and other yeasts of medical importance. In: *Manual of clinical microbiology* 8th edn. Ch. 114, P; 1693-1711. Murray PR; Baron E, and Pfaller MA, eds. ASM, Washington DC.
- **He XY, Meurman JH, Kari K, Rautemaa R, Samaranayake LP (2006):** In vitro adhesion of Candida species to denture base materials. *Mycoses*; 49:80-4.

- **Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W et al. (2002):** Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med*; 347:408–15.
- **Ho PL, Yuen KY (2000):** Aspergillosis in bone marrow transplant recipients. *Crit Rev Oncol Hematol*; 34:55-69.
- **Holmes AR, Gopal PK, Jenkinson HF (1995):** Adherence of *Candida albicans* to a cell surface polysaccharide receptor on *Streptococcus gordonii*. *Infect Immun*; 63:1827–1834.
- **Hospenthal DR, Beckius ML, Floyd KL, Horvath LL, Murray CK (2006):** Presumptive identification of *Candida* species other than *C. albicans*, *C. krusei*, and *C. tropicalis* with the chromogenic medium CHROMagar *Candida*. *Ann Clin Microbiol Antimicrob*; 5:1.
- **Howden BP, Slavin MA, Schwarzer AP, Mijch AM (2003):** Successful control of disseminated *Scedosporium prolificans* infection with a combination of voriconazole and terbinafine. *Eur J Clin Microbiol Infect Dis*; 22: 111-113.
- **Husain S, Muonz P, Forrest G, et al. (2005):** Infections due to *Scedosporium apiospermum* and *Scedosporium prolificans* in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. *Clin Infect Dis*; 40:89.
- **Iruretagoyena JR, Regulez P, Quindos Q, Ponton J (2009):** Antibodies to *Candida albicans* germ tube in two intensive care patients with invasive candidiasis. *Rev Iberoam Micol*; 17: 93-96.

- **Jabra-Rizk MA; Falkler JRW; Merz WG (2000):** Retrospective identification and characterization of *Candida dubliniensis* isolates among *C.albicans* clinical laboratory isolated from human immunodeficiency virus (HTV) infected and non-HIV infected individuals. *J Clin Microbiol*; 38 (6): 2423-2426
- **Jaeger EEM, Carroll NM, Choudhury S (2000):** Rapid detection and identification of *Candida*, *Aspergillitis*, and *Fusarium* species in ocular samples using nested PCR *J Clin Microbiol*; 38 (8): 2902-2908.
- **Jenkinson HF, Douglas LJ (2002):** Interactions between *Candida* species and bacteria in mixed infections. In: Brogden KA, Guthmiller JM (eds) *Polymicrobial Diseases*. ASM Press, Washington DC, Pp357-373.
- **Joanna F, Kleomenis S, Emmanuel R,(2007):** Invasive candidiasis in pediatric intensive care patients: epidemiology, riskfactors, management and outcome Aristotle University, Hippokration Hospital, 3rdDepartment of Pediatrics, Konstantinoupoleos, Thessaloniki, Greece 49,54642,
- **Johnson MD, MacDougall C, Ostrosky-Zeichner L (2004):** Combination antifungal therapy. *Antimicrob Agents Chemother*; 48: 693-715.
- **Jonathan A, Abelson BA, Theodore Moore MD, David Bruckner, Lin ScD, Jaime Deville MD and Karin Nielsen MD MPH (2005):** Frequency of Fungemia in Hospitalized Pediatric Inpatients Over 11 Years at a Tertiary Care Institution. *Pediatrics*; vol. 116. No.1, pp.61-67.

- **Khan Z, Abmad S, Mustafa AS, Chugh TD (2001):** Rapid detection and identification of medically important *Candida* species by nested PCR. 11th European Congress of Clin. Microbiol and Infect Dis. Istanbul, Turkey, P: 121, (Congress abstract book).
- **Kantarcioglu AS (2001):** Detection of phospholipase and protease production in clinical isolates of *Candida* species. 11th European Congress of Clinical Microbiology and infectious disease. Istanbul, Turkey, P: 340 (Congress abstract book).
- **Kaufman L and Reiss E (1998):** Sero diagnosis of fungal diseases. In: Manual of Clinical Laboratory Immunology, 4th edn, P: 506-528. Rose NR and Macario EC edr. ASM Press, Washington DC.
- **Kauffman CA (2004):** New antifungal agents. Semin Respir Crit Care Med; 25: 233-239.
- **Kendrick B (2001):** The Fifth Kingdom, 3rd ed. Focus Publishing/R. Pullins Company, Newburyport, Massachusetts, USA.
- **Kevin Berman (2006):** Tinea versicolor on A.D.A.M. www.yahoo.com
- **Kibbler CC, Seaton S, Barnes RA, Gransden WR, Holliman RE, Johnson EM, et al. (2003):** Management and outcome of bloodstream infections due to *Candida* species in England and Wales. J Hosp Infect; 54:18–24.
- **Knapp KM, MD, Flynn PM (2005):** Newer treatments for fungal infections. J Supportive Oncology; 3(4):290-298.

- **Kobayashi GS (2006):** Disease Mechanisms of Fungi. In: Baron S, Peake RC, James DA, Susman M, Carol AK, Singleton MJD, Schuenke S (eds): Medical Microbiology, 4th ed. The University of Texas Medical Branch at Galveston, Library of Congress.
- **Kontoyannis DP; Hachem R; Lewis RE (2003):** Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. *Cancer*; 98: 292-299.
- **Krcmery V and Barnes AJ (2005):** Non-albicans *Candida spp.* causing fungaemia: pathogenicity and antifungal resistance. *J. Hosp. Infect.* 50:243-260.
- **Kuhn DM, Chandra J, Mukherjee PC and Ghannoum MA (2002):** Comparison of biofilms formed by *C.albicans* and *C.parapsilosis* on bioprosthetic surfaces. *Infection and Immunity*; 70(2):878-888.
- **Kurtzman CP, Fell JW (eds.) (2002):** The Yeasts. A Taxonomic Study. Elsevier Science B.V., Amsterdam, The Netherlands.
- **Kwon-Chung KJ and Bennett JE (2000):** Candidiasis. In: *Medical mycol*; P: 280-337. Lea and Febiger Philadelphia.
- **Labraca JA, Grasmick EA, Kokkinos HM, Brickner DA (1998):** Critical evaluation of 4 weeks incubation for fungal cultures: is the fourth weeks useful? *J Clin Microbiol*; 35: 53-58.

- **Lamont RJ, Jenkinson HF (2000):** Adhesion as an ecological determinant in the oral cavity. In: Kuramitsu HK, Ellen RP (eds), *Oral Bacterial Ecology: The Molecular Basis*. Horizon Scientific Press, Wymondham, United Kingdom, pp. 131–168.
- **Lange M, Roszkiewicz J, Szczerkowska-Dobosz A, Jasiel-Walikowska E, Bykowska B (2006):** Onychomycosis is no longer a rare finding in children. *Mycoses*; 49:55-9.
- **Larocco MT (2002):** Reagents, Stains, and Media: Mycology, P 1686-1692. In: Murray PR (ed.) *Manual of Clinical Microbiology*, 8th edition. ASM Press, Washington, DC.
- **Larone DH (2002):** *Medically Important Fungi - A Guide to Identification*, 4th ed. ASM Press, Washington, D.C.
- **Leibovitz E, Luster-Reicher a, Amitai M, Mogilner B (2006):** Neonatal candidiasis: Clinical picture, management controversies and consensus, and new therapeutic options. 49: SI, 69-73.
- **Lequaglie CG; Basilico M; Massone PB (2002):** Lyposomal antifungal therapy and low toxicity in thoracic cancer patients in ICU. 8th International Congress of Infect. Dis Boston Massachusetts, USA, P: 96 (Congress abstract book).
- **Levinson WE (2008):** *Review of Medical Microbiology and Immunology*. 10th ed. (LANGE Basic Science). McGraw-Hill Medical.

- **Levy I, Shalit I, Birk E, Sirota L, Ashkenazi S, German B, et al. (2006):** Candida endocarditis in neonates: report of five cases and review of the literature. *Mycoses*; 49:43-48.
- **Lin MY, Carmeli Y, Zumsteg J, Flores EL, Tolentino J, Sreeramoju P, et al. (2005):** Prior antimicrobial therapy and risk for hospital-acquired *Candida glabrata* and *Candida krusei* fungemia: a case-case-control study. *Antimicrob Agents Chemother*; 49:4555-60.
- **Lin SJ, Schranz J, Teutsch SM (2001):** Aspergillosis case-fatality rate: systematic review of the literature. *Clin Infect Dis*; 32 :358 –366.
- **Linda RK; Elie CM; Clayton CE; Ciblak MA (2004):** Comparison of a new colorimetric assay with NCCLS broth microdilution method (M27-A) for antifungal drug MIC determination. *J Clin Microbiol*; 38 (6): 2334-2338.
- **Lipsett PA (2004):** Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations. *Clin Infect Dis*; 39:S193.
- **Lipsett PA (2006):** Surgical critical care: fungal infections in surgical patients. *Crit Care Med*; 34(9 suppl):S215.
- **Liu KH, Wu CJ, Chou HC, Lee NT Hung ST, Ko WC (2002):** Refractory candidal meningitis in an immunocompromised patient cured by capsofungin. *J Clin Microbiol*; 42 (12): 5950-5953.

- **Loo VG, Bertrand C, Dixon C, Vitye D, DeSalid B, McLean APH, et al. (2004):** Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit. *Infect. Control Hosp Epidemiol*; 17:360-364.
- **Lucas GM, Tucker P, Merz WG (2003):** Primary cutaneous *Aspergillus nidulans* infection associated with a Hickman catheter in a patient with neutropenia. *Clin Infect Dis*; 29:1594-1596.
- **Lye DCB, Hughes A, O'Brien D, Athan E (2005):** *Candida glabrata* prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. *Eur J Clin Microbiol Infect Dis*; 24:753-755.
- **Lyon R and Woods G (2004):** Comparison of the BacT/Alert and ISOLATOR blood culture systems for recovery of fungi. *Am J Clin Pathol*; 103: 660-662.
- **Magill SS, Shields C, Sears CL, Choti M, Merz WG (2006):** Triazole cross-resistance among *Candida* spp.: Case report, occurrence among bloodstream isolates, and implications for antifungal therapy. *J Clin Microbiol*; 44:529-535.
- **Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman B (2002):** Epidemiological, clinical and microbiological characteristics of late-onset sepsis among very low birth weight infants: a national survey. *Pediatrics*; 109: 34-39.

- **Malani AN and Kauffman CA (2007):** Candida urinary tract infections: treatment options. *Expert Rev Anti Infect Ther*; 5:277
- **Manno G, Scaramuccia A, Rossi R, Coppini A, Cruciani M (2004):** Trends in antifungal use and species distribution among Candida isolates in a large paediatric hospital. *Int J Antimicrob Agents*; 24 :627 – 628.
- **Marmel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS and Craven OE (2001):** Guidelines for the management of intravascular catheter-related infections. *Clin Infect Dis*; 32:1249-1272.
- **Marr K, Crippa F, Leisenring W (2004):** Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplant. *Blood*; 103: 1527-1533.
- **Martin TJ, Kerschner JE, Flanary VA (2005):** Fungal causes of otitis externa and tympanostomy tube otorrhea. *Int J Pediatr Otorhinolaryngol*; 69:1503-8.
- **Martinez J and Boogaerts M (2005):** The place for itraconazole in treatment. *J Antimicrob Chemother*; 56 Suppl; 1:133-138.
- **Maschmeyer G (2006):** The changing epidemiology of invasive fungal infections: new threats. *International journal of Antimicrob Agents*; 27(Suppl):S3-6.
- **Mayer F, Magadia R, Weinstein P (2004):** Laboratory diagnosis of bacteremia and fungemia. *Clin Infect Dis*; 15 (4): 1009-24.

- **McDonald LC, Weinstein MP, Fune J, Mirrett S, Reimer LG, Reller LB (2000):** Controlled comparison of BacT/ALERT FAN aerobic medium and BACTEC fungal blood culture medium for detection of fungemia. *J Clin Microbiol*; 39: 622-624.
- **McGinnis M (2000):** Image courtesy of M. McGinnis. Doctorfungus corporation
- **Merz WC and Roberts GD (2003):** Algorithms for detection and identification of fungi. In: *Manual of clinical microbiology*. 7th edn. Ch 94; P. 1167-1183. Murray PR, Baron E, Pfaller MA; eds. ASM, Washington DC.
- **Meunier F (2003):** Prevention and mycoses in immunocompromised patients. *Rev Infect Dis*; 9:408–416.
- **Miedzobrodzki J, Macura AB (2005):** Effect of staphylococcal proteinase on adherence of *Candida albicans* to mucous membrane cells in vitro. *Med Dosw Mikrobiol*; 45:245–247.
- **Mohammad A, Hanan M, Asmaa E, Sherin B et al. (2009):** pattern of fungal colonization in critically ill pediatric patients in Ain Shams pediatric ICU. pp 102-118
- **Mondal RK, Singhi SC, Chakrabarti A, et al. (2004):** Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study. *Pediatr Crit Care Med*; 5:561.

- **Morace G, Pagano L, Saguinetti M, Posteraro B, Mele L(1999):** PCR-Restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies. J Clin Microbiol; 37 (6): 1871-1875.
- **Morello FA, Mansilla AV, and Wallace MJ (2002):** Removal of renal fungus balls using a mechanical thrombectomy device. AJR AM J Roentgenol. 178: 1191-1193.
- **Mori F and Matsumura S (1999):** Rapid identification of Candida species. J Clin Microbiol; 36 (11): 3260-3265.
- **Narang A, Agraeal P, Chakraborti A, Kumar P (1998):** Fluconazole in the management of neonatal systemic candidiasis. Ind Pediatr; 33: 823-826.
- **NCCLS (1997):** method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard NCCLS document; M27-A [ISBN 1-56238-328-0].
- **Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC (2005):** The changing face of candidemia: emergence of non-candida albicans species and antifungal resistances. Am J Med; 100 (6): 617-23.
- **O'Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ (2003):** Infections in patients with hematological cancer: Recent developments. Hematology Am Soc Hematol Educ Program; 438-72.

- **O'Connor GT, Walter M, Mitchell H, Kattan M, Morgan WJ, Gruchalla RS, et al (2004):** Airborne fungi in the homes of children with asthma in low-income urban communities: The Inner-City Asthma Study. *J Allergy Clin Immunol*; 114(3):599-606.
- **Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT (2005):** Treatment of *Candida glabrata* infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. *Antimicrob Agents Chemother*; 49:4895-4902.
- **Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. (2003):** Antifungal susceptibility survey of 2,000 bloodstream *Candida* isolates in the United States. *Antimicrob Agents Chemother*; 47:3149–54.
- **Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelamn MA, Rex JH (2005):** Multicenter clinical evaluation of the (1-3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin Infect Dis*; 41 (5): 654-659.
- **Pagano L, Antinori A, Ammassari A, Mele L, Nosari A, Melillo L (2005):** Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. *Eur J Haematol*; 63: 77–85.
- **Pappas PH; Rex JH; Sobel JD (2004):** Guidelines for treatment of candidiasis. *Clin Infect Dis*; 38: 161-189.

- **Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz Edwards JE, Dismukes WE (2003)** . A prospective observational study of candidemia: epidemiology, therapy and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37:634-643
- **Patrick JL, Miller GR, Carr DL (1995):** Rapid calorimetric identification of *C. albicans*. J Clin Microbiol; 28 (2): 614-615.
- **Patton DD (2006):** Aspergillus, Health implication & recommendations for public health food safety. Internet J Food Safety, 8:19-23.
- **Pelz R, Lipsett PA, Swoboda SM, et al. (2000):** Candida infections: outcome and attributable ICU costs in critically ill patients. J Intensive Care Med; 15:255.
- **Perfect C and Schell M (2003):** Fluconazole resistant pathogen in patients infected with human immunodeficiency virus. Clin Infect Dis; 25: 161.
- **Persing DH (2003):** Polymerase chain reaction: Trenches to benches. J Clin Microbiol; 29 (5): 1281-1285.
- **Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN (2004):** In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn Microbiol Infect Dis; 48:101-105.

- **Pfaller MA, Pappas PG and Wingrad JR (2006):** Invasive fungal pathogens: Current epidemiological trends. *Clinical Infectious Diseases*; 43:S3-S14.
- **Pfaller MA, Diekema DJ.** Epidemiology of invasive candidiasis: a persistent public health problem. *Clin Microbiol Rev* **2007**Jan; 20 (1): 133-63
- **Piarroux R, Grenouillet F, Balvay P, et al. (2004):** Assessment of pre-emptive treatment to prevent severe candidiasis in critically ill surgical patients. *Crit Care Med*; 32:2443.
- **Pizzo PA, Poplack DG (2002):** Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins. p1,692.
- **Pozdorovkina W, Flemina AM, Beloborodova V (2002):** Analysis of arabinitol, mannose and mannitolmetabolites of several clinically important fungi in patients with candidiasis and aspergillosis. 8th International Congress of Infect. Dis Boston Massachusetts, USA; P: 95 (Congress abstract book).
- **Procop GW, Cockerill FR, Vetter EA, Harmsen WS, Hughes JG, Roberts GD (2000):** Performance of five agar media for recovery of fungi from isolator blood culture. *J Clin Microbiol*; 38: 3827-3829.
- **Rabkin A, Tjanoudaki M, Petriodiu E (2000):** Fungemia and resistance to antifungal agents in a children's hospital. 11th European Congress of Clinical Microbiology and Infection Diseases. Istanbul, Turkey, P: 170 (Congress Abstract Book).

- **Rang HP, Dale MM, Ritter JM (2000):** Antifungal drugs. In: Pharmacology, 4th ed. Ch 45, P: 720-724. Churchill Livingstone, London.
- **Raymond J, Aujard Y (2000)** Nosocomial infections in pediatric patients. A European multicenter prospective study. European Study Group .Infect Control Hosp Epidemiol 21:260-263
- **Redding SW, Marr KA, Kirkpatrick WR, Coco BJ, Patterson TF (2004):** Candida glabrata sepsis secondary to oral colonization in bone marrow transplantation. Med Mycol; 42:479-481.
- **Rex JH and Sobel JD (2001):** Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis; 32:1191.
- **Rezende JCP, Rezende MA and Saliba JL (2002):** Prevalence of Candida spp. in hospitalized patients and their risk factors. Mycose; s 45:306-312.
- **Richardson K (2008):** A Closer look at fungi in the Arnold Arboretum. Arnoldia; 66(4):13-21.
- **Richardson MD, Jones BL (2003):** Therapeutic guidelines in systemic fungal infections. Current Medical Literature, pp111-113.
- **Ritterband DC, Seedor JA, Shah MK, Koplin RS, McCormick SA (2006):** Fungal keratitis at the New York eye and ear infirmary. Cornea; 25:264-7.

- **Rodrigues AG, Ouna-Vaz C, MarJh PA, Martinez-Deoliveira J, Fonseaca AF (1999):** Regulatory effect of fibronectin on the morphogenesis of *C. albicans*, 9th European Congress of Clin. Microbiol and Infect. Dis Berlin, Germany, P: 391; (Congress abstract book).
- **Rodrigues AG, Ouna-Vaz C, Rarnos J (2001):** Impairment of phagocytosis following mycelium formation by *Candida* species, 11th European Congress of Clin. Microbiol and Infect. Dis Istanbul, Turkey, P: 336; (Congress abstract book).
- **Rosen GP, Nielsen K, Bowles L and Moore TB (2003):** Patterns of fungal infections in pediatric hematology and oncology patients at UCLA from 1991-2001 (abstract 1658). *Pediatr Res*; 53:291A
- **Rowen JL; Tate JM; Nordoff N; Passarell L; McGinnis MR (2001):** *Candida* isolates from neonates: frequency of misidentification and reduced fluconazole susceptibility. *J Clin Microbiol*; 37: 3735-7.
- **Ryan KJ (2002):** *Candida*, *Aspergillus*, and other opportunistic fungi. In: Sherris Medical Microbiology: An introduction to infectious diseases, 3rd edn. Kenneth J Ryan KJ edr. Copyright by Appleton and Lange.
- **Saag M, Graybill R, Larsen R, Pappas PG, Perfect JR, Powderly WG et al. (2000):** Practice guidelines for the management of cryptococcal disease. *Clin Infect Dis*; 30: 710-718.
- **Saiman L, Ludington E, Dawson JD, et al. (2001):** National Epidemiology of Mycoses Study Group: Risk factors for *Candida*

- species colonization of neonatal intensive care unit patients. *Pediatr Infect Dis J*; 20:1119.
- **Sallam A, Lynn W, McCluskey P, et al. (2006):** Endogenous Candida endophthalmitis. *Expert Rev Anti Infect Ther*; 4:675.
 - **Salle AJ (2007):** Fundamental Principles of Bacteriology (2^{ed} ed). McGRAW-HILL Book Company, INC. New York and London, p2.
 - **Sandven P, Qvist H, Skovlund E, et al. (2002):** NORGAS group and the Norwegian Study Group: Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. *Crit Care Med*; 30:541.
 - **Sanglard D and Bille J (2002):** Current understanding of the modes of action of and resistance mechanisms to conventional and emerging antifungal agents for the treatment of Candida infections. In: *Candida and candidiasis*, ed. Richard A; ASM Press; Washington, DC.
 - **Schwesinger G, Junghans D, Schroder G, et al. (2005):** Candidosis and aspergillosis as autopsy findings from 1994 to 2003. *Mycoses* 48:176, 2005 27. McNeil MM, Nash SL, Hajjeh RA, et al: Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. *Clin Infect Dis*; 33:641.
 - **Scott LJ and Simpson D (2007):** Voriconazole: a review of its use in the management of invasive fungal infections. *Drugs*; 67:269.

- **Segal E and Elad D (1998):** *Candida* species and blastoschizomyces capitatus. In: Topley and Wilson's Microbiology and Microbial Infections. 9th edn., Vol. 4, Ch 23, P: 423-451. Collier L, Balows A and Sussman M, eds. Arnold, London, Sydney.
- **Sendid B, Tabouret M, Poirot JL, Bonnin A, Caillot D, Poulian D (2003):** Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic *Candida* species. *J Med Microbiol*; 51 (5): 433-442.
- **Sendid B, Tabouret M, Poirot JL, Mathiwu D, Fuit JL, Poulian D (1999):** New enzyme immunoassays for sensitive detection of circulating *C. albicans* mannan and antimannan antibodies: Useful combined test for diagnosis of systemic candidiasis. *J Clin Microbiol*; 37 (5): 1510-1517.
- **Shay AC and Miller LG (2004):** An estimate of the incidence of candiduria among hospitalized patients in the United States. *Infect Control Hosp Epidemiol*; 25:894.
- **Shellow WVR (2000):** Management of superficial fungal infections. In: Primary care medicine: office evaluation and 1049. Goroll AH and Murlley AG, eds. Lippincott Williams and Wilkins, Philadelphia
- **Shetty D, Giri N, Gonzalez CE, Pizzo PA, Walsh TJ (2005):** Invasive aspergillosis in human immunodeficiency virus-infected children. *Pediatr Infect Dis J*; 16 :216 –221.
- **Shoelaces L (2006):** Hyphal Fungi on Flickr.www.yahoo.com

- **Sigmundsdottir G, Christensson B, Bjorklund LJ (2000):** Long-term effectiveness of treatment with Terbinafine versus itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol Mar; 138 (3): 353-357.
- **Simpson C, Blitz S and Shafran SD (2004):** The effect of current management funguria. J Infectio; n 49:248-252.
- **Singhi SC, Reddy TC, Chakrabarti A (2004):** Candidemia in a pediatric intensive care unit. Pediatr Crit Care med 5:369–374
- **Slavin MA, Szer J, Grigg AP, Roberts AW, Seymour JF, Sasadeusz J, et al. (2004):** Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J; 34(4):192-200.
- **Sobel JD (2002):** Controversies in the diagnosis of candiduria: What is the critical colony count? Infect Dis; 4:81-83.
- **Soubani AO, Chandrasekar PH (2002):** The clinical spectrum of pulmonary aspergillosis. Chest; 121:1988-1999.
- **Stedman (2005):** Stedman's medical dictionary. 28th ed, Lippincott Williams & Wilkins.
- **Steinbach WJ, Perfect JR, Cabell CH, et al. (2005):** A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infection; 51:230.

- **Steinbach WJ, Stevens DA (2003):** Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis; 37(3):S157–S187.
- **Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. (2002):** Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics; 110:285 –291
- **Strasser H, Butt TM and Vey A (2004):** Are there any risks in using entomopathogenic fungi for pest control, with particular reference to the bioactive metabolites of *Metarhizium*, *Tolypocladium* and *Beauveria* species? Biocontrol Sci. Technol; 10:717-735.
- **Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC (1995):** *Candida dubliniensis* sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology; 141:1507-1521.
- **Summerbell RC (2003):** *Aspergillus*, *Fusarium*, *Sporothrix*, *Pidraia* and their relatives, P. 273-498. In: Howard DH (ed.), *Fungi Pathogenic for Humans and Animals*, 2nd ed. Marcel Dekker, Inc, New York, NY.
- **Sutton DA, Fothergill AW, Rinaldi MG (2002):** *Guide to Clinically Significant Fungi*, 1st ed. Williams & Wilkins, Baltimore.
- **Takesue YC, Chiu YC, Wang JH, Lin HC, Su BH, Chiu HH (2004):** Nosocomial blood stream infection in a neonatal intensive care unit of a

- medical center: A three-year review. *J Microbiol Immunol Infect*; 35 (3): 168-72.
- **Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II (2005):** Posaconazole: a broad spectrum triazole antifungal. *Lancet Infect Dis*; 5: 775-785.
 - **Trick WE, Fridkin SK, Edwards JR; Hajjeh RA, Gaynes RP (2002):** Secular trend of hospital acquired candidemia among intensive care unit patients in United States during 1989-1999; *Clin Infect Dis* 35: 627-630.
 - **Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. (2007):** Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. *N Engl J Med*; 356:335–47.
 - **Vardakas KZ, Samonis G, Michalopoulos A, et al. (2006):** Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. *Crit Care Med*; 34:1216.
 - **Verghese SL, Padmaja P, Sutha , Mathew T, John ES (2000):** Rapid identification of fluconazole resistance using CHROMagar Candida. *Ind. J Pathol. Microbiol*; 43: 343-346.

- **Verweij PE, Van der Lee HAL, Rijs AJMM (2007):** The role of conventional diagnostic tools. In: Maertens JA, Marr KA (eds) Diagnosis of fungal infections. Informa HealthCare, 1 ed. Pp 29-30.
- **Viscoli C, Girmenia C, Marinus A, et al. (2000):** Invasive fungal infectin group of the European organization for research and treatment of cancer. Candidemia in cancer patients: A prospective, Multicenter surveillance study by the invasive fungal infection group of the European organization for research and treatment of cancer. Clin Infect Dis; 28:1071-1079.
- **Viviani MA, Cogliati M, Esposto MC, Prigitano A, Tortorano AM (2006):** Four-year persistence of a single Candida albicans genotype causing bloodstream infections in a surgical ward proven by multilocus sequence typing. J Clin Microbiol; 44:218-221.
- **Wahyningsih R, Freisleben HJ, Sonntag HG, Schuitzer P (2000):** Simple and rapid detection of C. albicans DNA in serum by PCR for diagnosis of invasive candidiasis. J Clin Microbiol; 38 (8): 3016-3021.
- **Walsh TJ, Ganzalez CE, Piscitelli S (2000):** Correlation between in vitro and in viva antifungal activities in experimental fluconazole resistant oropharyngeal and esophageal candidiasis J Clin Microbiol 38 (6): 2369-2373.
- **Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA et al. (2008):** Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. CID; 46:327- 360.

- **Walsh TJ, Sable C, DePauw B (2003):** A randomized, double-blind, multicenter trial of capsosungin vs liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients [Abstract M1 761]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology.
- **Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R, et al. (2000):** Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haematopoietic progenitor rescue. *Br J Haematol*; 110(2): 292-9.
- **Warren NG and Hazen KC (2004):** Candida, Cryptococcus and other yeasts of medical importance. In: *Manual of clinical microbiology* 7th edn. Ch. 95. P: 1884-1199. Murray PR, Baron EJ and Pfaller MA eds. ASM, Washington B.C.
- **Watson WJ; Abzyg MK; DeMuri G; et al. (1999):** Multicenter surveillance of invasive fungal disease in very low birth weight infants. *Pediatr Res*; 45: 275A.
- **White TC; Marr KA; Eowden RA (1998):** Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. *Clin Microbiol Rev*; 11: 382402.
- **Wiener AM, Bendel CM, ffess DJ, Eriandsen SL (2002):** Adherence of yeast and filamentous forms of *C. albicans* to cultured enterocytes *Grit Care Med*; 30 (3): 677-683.

- **Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, (2004):** A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLCL Collaborative Study Group. Clin Infect Dis; 31:1155–63.
- **Winston DJ, Maziarz RT, Chandrasekar PH (2003):** Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allo-geneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med.; 138 (9): 705-713.
- **Winter JSD (1992):** Fetal and neonatal adrenocortical physiology. In: Polin RA; Fox WW; eds. Fetal and Neonatal Physiology, Philadelphia: WB Saunders; 2: 1829-1841.
- **Wisplinghoff H, Bischoff T, Tallent SM, et al (2004):** Nosocomial Blood stream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004 Aug 1; 39 (3): 309-17
- **Wu T and Samaranayake LP (2003):** The expression of secreted aspartyl proteinases of Candida species in human whole saliva. J Med Microbiol; 48 (8): 711-720.
- **Xisto Sena Passos, Werther Souza Sales, Patrícia Jackeline Maciel, Carolina Rodrigues Costa, Karla Carvalho Miranda, Janine de Aquino Lemos, Miranildes de Abreu Batista, Maria do Rosário and**

- Rodrigues Silva (2005):** Candida colonization in intensive care unit patients' urine. Mem. Inst. Oswaldo Cruz; vol.100 no.8 Rio de Janeiro.
- **Yoshida M, Obayashi A, Iwama A, Ito M, Tsunoda S, Suzuki T, Muroi K, Ohta M, Sakamoto S, Miurcl Y (1997):** Detection of plasma (1->3)-p-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremomum ftmgaemias J Med Vet Mycol; 35: 371-374.
 - **Zaas AK and Alexander BD (2005):** Echinocandins: role in antifungal therapy: Expert Opin Pharmacother; 6 (10): 1657-1668
 - **Zaoutiz Te, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C (2005).** The epidemiology and attributable outcomes of candidemia in adult and children hospitalized in the United States:A propensity analysis .Clin Infect Dis 41:1232-1239
 - **Zaugg C, Zepelin MB, Reichard U, Sanglard D and Monod M (2001):** Secreted Aspartic Proteinase family of candida tropicalis. Infection and Immunity; 69(1): 405-412.
 - **Zirbes JM and Milla CE (2008):** Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis". 23 April; 43(6):607-610.